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Abstract The purpose of this work was to develop a
consolidated set of guiding principles for reporting of
population pharmacokinetic (PK) analyses based on input
from a survey of practitioners as well as discussions be-
tween industry, consulting and regulatory scientists. The
survey found that identification of population covariate
effects on drug exposure and support for dose selection
(where population PK frequently serves as preparatory
analysis to exposure–response modeling) are the main ar-
eas of influence for population PK analysis. The proposed
guidelines consider two main purposes of population PK
reports (1) to present key analysis findings and their impact
on drug development decisions, and (2) as documentation
of the analysis methods for the dual purpose of enabling
review of the analysis and facilitating future use of the
models. This work also identified two main audiences for
the reports: (1) a technically competent group responsible
for in-depth review of the data, methodology, and results,
and (2) a scientifically literate, but not technically adept
group, whose main interest is in the implications of the
analysis for the broader drug development program. We
recommend a generalized question-based approach with
six questions that need to be addressed throughout the re-
port. We recommend eight sections (Synopsis, Introduc-
tion, Data, Methods, Results, Discussion, Conclusions,
Appendix) with suggestions for the target audience and
level of detail for each section. A section providing general
expectations regarding population PK reporting from a
regulatory perspective is also included. We consider this an
important step towards industrialization of the field of
pharmacometrics such that non-technical audience also
understands the role of pharmacometrics analyses in deci-
sion making. Population PK reports were chosen as rep-
resentative reports to derive these recommendations;
however, the guiding principles presented here are appli-
cable for all pharmacometric reports including PKPD and
simulation reports.
Keywords Pharmacometrics  Population
pharmacokinetics  PK reporting  Regulatory submission 
Best practices
Introduction
Since the early development of software for conducting
non-linear mixed effects modelling in the late 1970s by
Sheiner and Beal [1], population pharmacokinetics (PK)
has evolved into one of the core data analysis methods
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utilized in drug development. Population PK is useful be-
cause it allows systematic integration of data that may have
been collected in different ways from a variety of sources,
and because it facilitates characterization of the effects of
intrinsic patient characteristics or extrinsic treatment or
study design attributes on drug exposure into a single,
cohesive mathematical framework. Further it allows the
simultaneous characterization of main, expected effects
together with inter- and intra-subject variability on phar-
macokinetic behaviour. These models may be used to
simulate expected exposure metrics (e.g. AUC, Cmax, Cmin,
Cavg, etc.) under new conditions such as alternative dosing
regimens or to derive individual PK parameter/exposure
metrics that can be used in subsequent assessment of ex-
posure–response relationships. As the utility and impact of
pharmacometrics generally, and population PK specifical-
ly, has grown, so has the need for consistency in the ways
in which these analyses are conducted and reported.
In this article, we present a consolidated set of guiding
principles for reporting of population pharmacokinetic
analyses based on survey input as well as discussions be-
tween industry, consulting and regulatory scientists. Our
goal was to form pragmatic recommendations in order to
(1) enhance communication of analysis findings; (2)
broaden the impact of population PK reports; and (3) fa-
cilitate efficient report development and review.
Motivation
In general, a population PK report serves two critical
functions. The first is to communicate the key findings of
the analysis in a language that is understandable to all
stakeholders. In many organizations, stakeholders fre-
quently include knowledgeable readers from varied fields
of expertise in addition to experienced pharmacometri-
cians. The report should describe the analysis objectives
and intended application, clinical relevance of the findings,
and place the results in the appropriate drug development
context.
The second major purpose of the population PK report is
to provide detailed documentation of analysis methods and
conduct, enabling the work to be reproduced if needed, or
to facilitate review (internal and/or regulatory). The
document needs to include description of the data used and
reasoning by which population PK models were developed.
Further, the report needs to include sufficient evidence that
the model adequately describes the data, and, thus, can be
reasonably used to, for example, predict future exposure in
the population(s) of interest. This documentation needs to
be sufficiently detailed to allow a reader to reproduce the
results described in the document. This function of the
report is critical not only for formal reviewers, but also for
pharmacometricians who may need to expand on or
otherwise refer to a given analysis months or years after it
was originally performed.
In the authors’ experience, there is substantial variation
in the content and formatting of population PK reports
generated by different organizations and even among
pharmacometricians within a single organization, and less
than clear consensus as to what parts of a given analysis
should be highlighted to maximize the usefulness of the
results. Frequent shortcomings of population PK reports
include:
• Analysis objectives and application not clearly stated
• Important findings and their relevance to analysis
objectives are overshadowed by technical detail
• Many graphical and tabular data displays are used to
examine and qualify models, but provide little insight
into the impact of the key findings
It is anticipated that wide implementation of practical
reporting guidelines should have the overriding benefit of
facilitating clear communication of the analysis results to
all interested stakeholders. The report should highlight
analysis objectives, demonstrate how the analysis met
those objectives, facilitate ready access to the results and
describe their clinical impact, and enhance readability of
key sections to a generally knowledgeable audience. Ad-
ditionally, implementation of these guidelines should in-
crease the efficiency of reviewing these reports by
enhancing the consistency of formatting and content in the
documents, allowing the reader to easily locate the infor-
mation critical to assessing the validity and strength of the
findings. Use of standardized reporting formats should
enable drug development organizations to produce these
documents more efficiently, utilizing automation where
appropriate, and eliminating needlessly repetitive descrip-
tion of standardized methods. Finally, application of re-
porting standards constitutes an important step toward the
industrialization of pharmacometrics [2].
Previous work
Several authors have touched on the methodology for
population PK conduct and reporting over the past decade.
There have been many software and methodological ad-
vances since the first FDA guidance on popPK was final-
ized in 1999 [3]. Wade [4] published guidelines specific to
the Swedish Medical Products Agency, and a guidance for
population PK was formalized by EMA in 2007 [5].
Notable about these recommendations is an emphasis on
very detailed description of the model and model qualifi-
cation and less emphasis on highlighting the purpose and
application of the models. More recently, best practices
utilized in two industry-based pharmacometrics groups
have been published [6, 7] focusing on guidelines for
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general population PK modeling within single companies
and Jamsen et al. [8] published a journal’s perspective on
reporting population PK studies.
Approach
This work was carried out under the auspices of the Model-
Based Drug Development (MBDD) Consortium, a working
group comprised of representatives from American Society
of Clinical Pharmacology and Therapeutics (ASCPT),
American College of Clinical Pharmacology (ACCP),
American Association of Pharmaceutical Sciences (AAPS),
and the International Society of Pharmacometrics (ISoP).
Our group included representatives from industry, phar-
macometric consultancies, and the FDA.1
In developing our recommendations, we initially con-
ducted a survey of population PK reporting practices
among interested scientific society members in order to
identify preferences and practices that are common among
practitioners. These results formed the starting point for
development of the guiding principles. The form and use of
population PK reports were further discussed in order to
highlight aspects of the reporting process and report con-
tent that function well, and those that did not. Topics in-
cluded current (and aspirational) target audiences for the
reports, examination of the functional purpose of these
documents, degree to which some practices are sufficiently
standardized to make it less critical to include their ex-
haustive discussion in the report, and depth of detail in the
documentation that allows an analysis to be qualified as fit
for purpose.
The survey results and emerging recommendations were
presented at each of the MBDD member society national
meetings in order to encourage comments from the broader
pharmacometrics community, and these suggestions are
incorporated here where appropriate. We especially wanted
to ensure that we developed guiding principles for report-
ing that could be readily adopted across a spectrum of
organizations, and that they would be sufficiently detailed
to be useful, while being general enough to be broadly
applicable. In this work, we have focused primarily on
comprehensive reports describing complete population PK
analyses, rather than memo-style reports or publications.
Objectives
The objectives of this work were to:
(1) Develop and implement a survey of common
population PK analysis and reporting practices
among pharmacometrics practitioners,
(2) Present the survey results to interested stakeholders
including industry, consulting and regulatory scien-
tists in order to generate discussion on best reporting
practices,
(3) Based on this broad consultation, develop a con-
solidated set of reporting guidelines for population
PK analyses.
Survey description and results
Description
A single-round electronic survey was conducted in order to
elicit information on current views and practices on re-
porting of population PK analyses. It included 91 questions
about different aspects of respondents’ experiences and
preferences regarding population PK analyses and report-
ing. These were organized into five primary sections: (1)
respondent experience; (2) purpose and impact of popula-
tion PK report; (3) components of population PK report;
(4) model diagnostics; and (5) modeling practices. The
survey mainly contained multiple-choice questions. The
survey is available in the online supplemental material.
Approximately 3200 members of the MBDD consortium
member organizations, including AAPS Pharmacometrics
Focus Group (formerly the Population PK, and Modeling
and Simulation Focus Groups), ACCP, ASCPT Pharma-
cometrics and Pharmacokinetics section, and ISoP, were
invited to participate in this survey. The survey was
available online during the period 6th to 26th November,
2012.
Survey results
A total of 351 surveys (11 % response rate) were com-
pleted and available for analyses. All survey responses
were included, whether or not a respondent had completed
all questions. Table 1 lists the survey sections and fraction
of respondents with complete responses by section.
Respondent characteristics
The respondents were generally experienced in population
PK analysis, with 87 % having at least 5 years post grad-
uate experience in pharmaceutical science, and with 72 %
considering their knowledge in population PK analyses at
least intermediate (Table 2). Sixty percent (60 %) of re-
spondents had personally performed, and 81 % had
1 Views expressed in this manuscript reflect the opinion of the
individual contributors, and do not reflect the position of the U.S.
Food and Drug Administration.
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reviewed population PK analyses in detail in the 2 years
prior to the survey. The survey did not interrogate the type
of organization in which the respondents worked, i.e. in-
dustry, regulatory or academic, etc.
Report audience and use
When asked about the main audience of population PK re-
ports, 44 % of respondents answered that regulatory review-
ers comprised the main audience for these reports (Table 3),
while 38 % indicated the main audience as internal technical
experts (pharmacometrics, PK, clinical pharmacology, bio-
statistics). Internal non-technical experts including clinical,
regulatory and governance were considered by only 15 % of
respondents as the main audience. The results were consistent
regardless of the respondents’ experience or knowledge in
population PK analyses.
Fifty-two percent (52 %) of respondents indicated test-
ing and identification of covariate effects or effects in
special populations as the most important purpose of
population PK reports, followed by integration of PK in-
formation across clinical trials (25 %) (Table 3). Formu-
lation of dosing recommendations for clinical trials or
labeling (57 %) and ground work for exposure–response
analysis (30 %) were the two most important impacts of
population PK reports identified by respondents.
Table 1 Survey sections and
fraction of respondents by
section
Section Percentage of respondents
Respondent characteristics 99
Respondent experience and use of reporting 99





experience and knowledge with
population PK analyses
Question Category Percentage










Table 3 Perceived audience
and purpose for population PK
reports
Question Category Percentage








Major impact of population PK analyses Dose selection 57
Support PK/PD analysis 31
Regulatory checkbox 8
Other 4
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Report components
A list of 37 common content elements (including main
sections, subsections and other frequently reported analysis
elements) found in a typical population PK report was
queried in the survey to identify respondents’ preferred
location and perceived importance in a report. The options
for preferred location were ‘‘Report Body’’, ‘‘Combine
with Another Section’’, or ‘‘Appendix’’. Approximately
75 % of the respondents provided a response in this sec-
tion. Respondents were also asked to rate the importance of
a given element on a 1–5 scale, with 5 being ‘‘Extremely
important’’ and 1 being ‘‘Not Very Important’’. A final
question queried the preferred audience for each section.
We report on the preferred location and importance ques-
tions here (full survey results are available upon request
from the authors). For each content element, a weighted
importance was calculated as the sum of the product of the
numeric response value by the percentage of respondents




r  Prð Þ=nlevel
where nlevel is the number of possible response levels, r is
the response value (1–5), and Pr is the percentage of re-
spondents giving that response.
As shown in Fig. 1, there was a clear correlation be-
tween a desire to include a section or element in the body
of the report and the perceived importance of the section.
The exception was for introductory material, with over
95 % respondents preferring to see the Introduction in-
cluded in the report body, but assigning relatively little
importance to this section. The elements that [90 % of
respondents preferred to be included in the report body and
which had perceived weighted importance[90 % included
the Synopsis, Conclusions, Discussion along with Final
Model description, and Application/Interpretation of
Model Results, both within the ‘‘Results section’’.
None of the content elements in the ‘‘Methods section’’
had weighted perceived importance over 85 % or had over
90 % of respondents preferring to see a given element in
the report body (Fig. 2). The three Methods elements with
over 80 % of respondents preferring to see them in the
report body were the ‘‘General Modeling Approach’’,
‘‘Study Design’’ and ‘‘Population Description’’.
Within the ‘‘Results section’’ (Fig. 3), the overall ‘‘Co-
variate Analysis’’ and ‘‘Structural Model Description’’ each
had perceived importance [85 % and over 85 % of re-
spondents preferring inclusion in the report body (in ad-
dition to the ‘‘Final Model Description’’ and ‘‘Application/
Interpretation of the Results’’, referred to above).
These results suggest that respondents found the most
value in overall descriptions of the analysis, methods and
results with particular importance being placed on higher
level content elements. Overall, based on these data and
information from the survey comments, the population PK
report is perceived as a communication tool summarizing
the general methodology and study data while focusing on
the final model and its clinical application.
Model diagnostics and modeling practice
The next two survey sections addressed questions related to
what supporting analysis should be included in order for
the report to be considered a credible, well-qualified
Fig. 1 Components of a population PK report and their perceived
importance. Each symbol represents the response for a single report
section, subsection or content element
Fig. 2 Preferred location and importance of content elements within
‘‘Methods section’’: Data Sources (circles): 1. overall data sources 2.
study design 3. population. Data Handling (triangles): 1. overall data
handling 2. handling of missing data 3. handling of covariates 4.
handling of outliers 5. data exclusions. Modeling and Statistical
Methods (squares): 1. general approach 2. structural model develop-
ment 3. random effects 4. covariate model development 5. model
qualification 6. simulation methods. Note: X-axis jitter added to data
to distinguish overlapping values
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document supporting the analysis recommendations. Sur-
vey respondents were asked to rate the utility of different
model diagnostics and were queried about specific prac-
tices they employ in developing a population PK model.
Similar to the survey section on content elements, re-
spondents were asked their preferred location for different
model diagnostics, and to rate the importance of each
diagnostic. Additionally, respondents were asked how
frequently a given diagnostic plot or analysis should be
included in the report. Possible responses were ‘‘always’’,
‘‘optional’’, or ‘‘in special cases’’. Response results were
divided into three categories: generally included: defined
as those that[80 % of respondents would include in the
report body and with[80 % weighted importance; inter-
mediate inclusion: those with 70–80 % weighted
importance and inclusion, and as needed: those diagnos-
tics with\70 % weighted importance or that\70 % of
respondents indicated they always include in the report
body (see Table 4).
Generally, respondents confirmed that model diagnos-
tics are an important component of any population PK
report. There is also some overlap in the diagnostic ana-
lyses that were queried; for example, a visual predictive
check (VPC) is a type of comparison of the model results to
observations [9]. As shown in Table 4, standard diagnos-
tics related to precision of parameter estimates, estimates
of inter-subject and residual variability, and direct com-
parison of model predictions to observed data were in the
generally included category. Diagnostics, such as condi-
tional weighted residuals versus population predicted value
(PRED) or shrinkage, that could be considered more
closely related to statistical performance of the model were
in the two categories that might be less frequently included
in the report body.
Modeling practice
To elicit participants’ attitude towards modeling practice,
we asked nine questions that potentially could influence
acceptance, perceived beliefs, and usage of certain mod-
eling methodologies. A total of 63 % of respondents an-
swered at least one of the nine questions in this section of
the survey. Most of the respondents who did not answer
questions in this section described themselves as having
basic or no knowledge of population PK analyses. Each
question in this section queried respondents’ degree of
acceptance of different PK modeling practices. Possible
responses to the questions were (1) ‘‘Of course!’’, (2)
‘‘Usually’’, (3) ‘‘Sometimes, with justification’’, and (4)
‘‘Never’’.
The majority of respondents, 60 %, indicated that it is
acceptable, ‘‘sometimes with justification’’, to include a
covariate effect on parameters with no random effect.
Similarly, 53 % indicated that it is occasionally acceptable
to add a random effect based on goodness-of-fit or objec-
tive function value ‘‘with justification’’.
Fig. 3 Preferred location and importance of Results content ele-
ments: Data Description (light blue square): 1. demographics 2.
covariate distributions 3. sampling time distribution 4. display of raw
data versus time 5. other. Structural Model Description (orange
circle): 1. overall random effects (light yellow triangle): 1. overall 2.
residual variability 3. inter-individual variability 4. inter-occasion
variability. Covariate Analysis (green diamond): 1. overall 2.
covariates tested 3. covariates selected. Final Model (black square):
1. overall. Model Qualification (gray circle): 1. overall. Application/
Interpretation of Model Results (red triangle): 1. overall 2. simulation
results 3. size of identified differences among covariates. Note: X-axis
jitter added to data to distinguish overlapping values
Table 4 Model diagnostics versus inclusion category
Generally included Intermediate inclusion As needed
Precision of estimates PRED vs. DV Shrinkage
Comparison of model results to observations IPRED vs. DV Bootstrap
Magnitude of residual variability CWRES vs. Time Random effects distributions
Magnitude of interindividual variability CWRES vs. PRED OMEGA matrix
Visual predictive check Model predictions and observed data vs. time Histogram of Etas
Traditional PK summary parameters Case-deletion
Parameter values vs. covariates of interest Model development trail
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Fifty-nine percent (59 %) of respondents indicated that
it is sometimes acceptable to report a final model that did
not successfully estimate the model variance–covariance
matrix (i.e. completion of the $COV step in NONMEM),
‘‘with justification’’, while 65 % would sometimes accept
the use of first order (FO) estimation. Simulation-based
estimation methods were considered acceptable by 42 % of
respondents, again, with appropriate justification. Respon-
dents reported using a range of simulation-based estima-
tions methods; however SAEM was accepted by the
majority of respondents as an acceptable simulation-based
estimation method.
To put covariate analysis into context, we asked if co-
variates could be excluded due to large shrinkage, very
small effect size, or lack of precision. Forty-seven percent
(47 %) reported ‘‘usually’’ excluding covariate effects due
to large shrinkage, with 42 % excluding covariate effects
for very small effect size, and 44 %, removing covariates
from the model because of lack of precision in the pa-
rameter estimates.
The final question referred to the preferred method for
handling BLOQ values, specifically whether the re-
spondent prefers to employ the so-called M3 method,
which maximizes the likelihood considering measurable
values together with the likelihood of observations being
BLOQ [10]. Forty-four percent (44 %) of respondents
reported using the M3 method to handle values that are
BLOQ. The key finding in this section was that the
survey respondents found many methodological varia-
tions acceptable as long as their use is adequately
justified.
General recommendations
Key questions to address
The dual objectives of a population PK report are (1) to
communicate key findings and recommendations to stake-
holders (e.g. internal stakeholders or regulatory agencies);
and (2) to make the analyses reproducible by summarizing
the methods, data used, and results obtained in the analysis.
To achieve that impact, the population PK report should
address the following questions:
• Why do the analysis?
• What information did you use?
• How did you do it?
• What did you find out and why does it matter?
• Is the model good enough?
• What are the key assumptions or limitations to the
analysis interpretation?
Why do the analysis?
It is critical to obtain alignment of objectives with key
internal stakeholders before embarking on a population PK
analysis, and it is important that the analysis objectives be
spelled out in the population PK report. A data/modeling
analysis plan (DAP) can be a useful tool to prospectively
facilitate such alignment, provided care is taken to spell out
the key strategic questions the analysis is intended to ad-
dress, in addition to describing the planned technical con-
duct of the analysis.
What information did you use?
A detailed description of the data used for the analysis is
important in order to assess whether the dataset is adequate
to support the intended purpose of the analysis and whether
certain limitations can be identified a priori. For example,
identification of the influence of a particular covariate may
not be supported by an analysis based primarily on small
Phase 1 studies. Conversely, model estimation of peak
plasma concentration or shape of the PK profile is difficult
to assess by analysis of sparse, trough concentration
samples.
How did you do it?
This technical portion of the report will describe the gen-
eral modeling approach, and should also include the rele-
vant specific technical details used in conducting the
analysis.
What did you find out and why does it matter?
The report needs to highlight the main findings and relate
these results to the initial analysis objectives. Further, the
report needs to place the results in the overall context of
prior knowledge about the compound and the intended
patient population. Clear, concise descriptions of the key
findings, analysis context, and analysis strengths and
weaknesses will allow informed decisions to be made on
the basis of the analysis.
Is the model good enough?
The report should include demonstration that the model
describes the data adequately and is sufficiently detailed to
be fit for the purpose outlined in the analysis objectives.
Rationale for modeling assumptions and choices should be
described to allow the reader to assess whether the con-
clusions are robust enough to support recommendations
based on the results.
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What are the key assumptions or limitations
to the analysis interpretation?
No model completely describes all aspects of a given
dataset. The strengths and weaknesses of the analysis and
possible limitations of the underlying data should be dis-
cussed to increase the confidence in the conclusions and
help the readers assess the degree to which the findings
reflect true characteristics of the target population or are
dependent on model assumptions or data limitations.
Report audiences
The survey results suggested that the main audiences for
population PK reports were regulatory reviewers and in-
ternal technical experts, two groups that are generally
technically adept. However, in the authors’ experience,
there is a significant fraction of internal and external
stakeholders who do not have specific technical expertise
in pharmacometrics, but who often play an important role
in reviewing the reports and in making decisions based on
the analysis results.
To maximize the impact of population PK analysis, key
findings need to be reported in such a manner that a ma-
jority of informed stakeholders can understand the major
findings and feel confident, with the participation of
pharmacometricians, in making decisions based on the
analysis. Thus, the population PK report should include
portions that are meant to be accessible to all readers.
These sections should include description of the problem to
be addressed and the key analysis findings, each expressed
in language that a scientifically literate audience would be
able to understand. This means, for example, that covariate
effects would be described in terms of their impact on
concentration or measures of overall drug exposure, rather
than their impact on specific clearance or volume pa-
rameter values. These report sections could be described as
being primarily decision-focused.
It is also clear that the population PK report serves a
critical purpose in facilitating technical review of the work
and in documenting the analysis for future reference. In
this role, the report needs to serve as a repository for the
technical details regarding the methodology, model
qualification, and detailed analysis results. These analysis
documentation sections should be written so that a tech-
nically adept reader can comprehensively understand the
analysis methodology and detailed results.
In summary, there are two key audiences for population
PK reports: (1) well-informed but non-technical readers
whose interest is in the main analysis results, its ramifi-
cations, and the ability of the analysis to support key drug
development decisions, and (2) technically adept readers
whose task is to review the analysis for technical soundness
or who may be responsible for repeating or expanding the
analysis at a later time. Different sections of the report
should be written to address one or both of these audiences.
Role of data or modeling analysis plan
Population PK analyses are focused on estimation of key
parameter values, variability between subjects, and co-
variate effects on exposure. An important concern is the
degree of certainty with which these characteristics can be
credibly assessed from a given dataset and analysis
methodology. A DAP is often prepared in order to
prospectively describe the data, methods and analysis ob-
jectives and to help foster acceptance of the planned
population PK analysis by a drug development team. If a
DAP has been prepared, the DAP should be seen as a useful
planning and communication tool, but cannot precisely
prespecify a particular method of analysis or model-build-
ing path. For analyses that are carried out over an extended
period of time or that are updated as data become available,
the DAP may be seen as a living document. Thus, there may
not be a need to exhaustively address deviations from the
plan in the body of the population PK report. However, it is
recommended that one critically assess the need for de-
viations from the plan, and it is often valuable to the reader
to understand what was learned in the current analysis that
may have caused a given deviation.
Important elements to include in a DAP are the purpose
for performing the analyses, key questions/applications the
analysis will address, prior information from e.g. previous
trials, compounds and/or literature, choice of data, lists of
covariates to be examined and general methodologies, as
well as specific assumptions and limitations.
Guidelines for report sections
Overall report structure
In considering the overall report structure, it was deemed
important to have the overall structure be consistent with
current practices in general scientific reporting and with
other technical reports that are found in regulatory sub-
missions. We suggest that the population PK report include
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VIII. Appendix (if needed)
This structure is similar to the overall structure recom-
mended in previous population PK regulatory guidance [3,
5]. Recommended guiding principles for each of these re-
port sections are detailed below.
Synopsis section
• Audience: all readers
• Focus area: objectives and impact of analysis
The Synopsis is arguably the most important section in the
population PK report. The Synopsis should be a stand-
alone section that states the recommendations, and sum-
marizes the evidence supporting them in clear language
that can be understood by all stakeholders. If the analysis
results in a labelling change, portions of the synopsis might
be included in the Summary of Clinical Pharmacology as
part of an NDA review. This section should highlight the
objectives of the analysis and provide a high level sum-
mary of the data and the methodology utilized. Examples
of key results might include a list of covariates tested and
identification of those that have meaningful impact on the
PK of a drug, or if dosage adjustments are warranted in
particular populations. Results displayed in this section
should be shown or described in terms of the impact on
drug concentration or exposure, and not in terms of specific
PK parameters, in keeping with the goal of communicating
the analysis results and impact to a generally informed, but
not necessarily technically inclined audience. In addition,
important summary graphs or tables that support decision
making could be incorporated in this section, for example,
forest plots depicting the impact of covariates on Cmax or
AUC. This section should be reasonably succinct, and not a
lengthy repetition of material found in the body of the
report. For a typical analysis, this section might be ap-
proximately two pages long, though, obviously, the scope
and complexity of the material to be presented will dictate
the length of this or any other section.
Introduction section
• Audience: all readers
• Focus area: background and motivation for the analysis
Similar to the Synopsis, the Introduction is generally tar-
geted for all audiences and should therefore contain perti-
nent information that provides context and motivation for
the analysis. This section should provide sufficient back-
ground information on the pharmacology of the compound,
the target indication and the PK characteristics based on
historical information and the stage of drug development to
motivate the analysis and approach. A clear statement of
the analysis objectives is an essential component of this
section. Typically, this information would be summarized
in a single page.
Data section
• Audience: technical readers
• Focus area: data sources, relevant aspects of study
design, description of data handling and issues
In this section, a description of the study data and the pro-
cesses used to generate the analysis data set should be given.
The data upon which the analysis is based is a key de-
terminant of whether the results can support the intended
objectives. Therefore, it is critical that a description of the
data used in the analysis along with a description of any
modifications or derived quantities be included in the re-
port. This section would normally include a short de-
scription of the study or studies that generated analysis
data, with special importance attached to the number of
subjects, number and timing of samples per subject, disease
status in each study, and any pertinent demographic or
laboratory data. The data summarized in this section should
be consistent with the stated analysis objectives. Typically,
approximately two paragraphs per protocol would be suf-
ficient to summarize pertinent study data. It is also quite
useful to show this information in tabular form.
Specific details regarding, for example, rules for removal
of data with missing information, imputation of missing co-
variate information, removal of outliers, etc. might be pro-
vided in the body of the report together with the rationale for
specific decisions made during the creation of the datasets.
Listings of specific data points removed from the dataset,
along with the reason for omission would normally be in-
cluded in an appendix. If datasets aremodified over the course
of the analysis, the file name of each version of the dataset
must be unique and provided in the appendix. This allows
verification of the different datasets utilized for the various
model files.
Table 5 provides guidelines with respect to the data
elements that are considered to be essential in the main
body of the report versus those that could be placed in an
appendix in supplementary material. If a DAP exists, that
document may be referenced to avoid redundancies in the
report while highlighting only the deviations from the
proposed analyses in the main body of the report.
Methods section
• Audience: technical readers
• Focus area: technical methods with focus on the most
important aspects, balanced with other details to be
included in Appendix
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Consistent with the purpose of any scientific communica-
tion, a population PK report needs to provide sufficient
detail of the modeling exercise to allow reproduction of the
analysis. However, most methodological detail would
normally be of interest to a primarily technical audience,
and certain methodologies may be considered sufficiently
standardized to be described in an appendix, or to be in-
cluded by reference (Fig. 2). Dependent on whether a DAP
exists, some of the elements could be referenced to the
DAP (as a stand-alone document or as an appendix to the
report) rather than being repeated in the report body. If a
DAP does not exist, standard technical details (e.g., con-
struction of the structural model, standard methods for
covariate search) could be included in an appendix while
the estimation methods specific to the analysis should be
included in the body of the report. Table 6 provides
guidelines with respect to the elements of the method
section that are considered to be essential in the main body
of the report versus being embedded in an appendix.
Results section
• Audience: technical readers
• Focus area: final model description, diagnostics and
qualification
The results section targets a technical audience and details
the specific outcomes and applications of the analysis.
Recommended elements of the results section include:
• Model development table for key models, including
structural models and covariate evaluations
• Reasoning for selection of key models at each stage of
the model development process
• Form of the best selected model
• Final parameter estimates, including uncertainty (SE)
• Model performance/qualification
• Simulation or other model applications, e.g., impact of
significant covariates on PK parameters, exposure and/
or dose selection
A description of the best selected model and the appli-
cation of the model to address the project objectives should
normally be included in the body of the report. This rec-
ommendation is consistent with the survey results (Fig. 3).
Key model qualification plots (see examples in [5]) should
also be presented here. The most critical element of the re-
sults section is the interpretation and/or application of the
model. Supporting tables or figures that address the objec-
tives and enhance communication of the results of the ana-
lysis are essential. Figures should be clearly labelled with
text and symbols large enough to be clearly legible. Judicious
use of color can greatly aid in distinguishing different plotted
elements. Forest plots (see for example [8]), density distri-
butions or histograms may be useful tools to visualize the
results and enhance their interpretation.
Depending on the purpose of the report and to improve
readability for non-technical audiences, other elements may
be included in the body of the report or in one or more ap-
pendices. For example, if the primary purpose of the report is
to inform dose selection, this should be themajor focus of the
results in the body of the report and all supporting model
development results may be consolidated in an appendix.
A description of the development pathway needs to
appear somewhere in the popPK report. It may be appro-
priate to place an abbreviated table describing only the key
models examined in the report body, with the detailed
modeling table placed in the appendix. Obviously, place-
ment of model development results in an appendix does not
lessen the importance of a rigorous model selection and
qualification process. The rationale for model selection
must always be clearly presented and the model must be
adequately qualified per current guidelines (FDA/EMA
guidelines) and state-of-the-art methodologies. Table 7
Table 5 Guidelines for placement of data elements
Generally included in main body of report May or may not be included
in report body
Usually included in appendix
Description of studies in source dataset Methods for covariate imputation Excluded data and the reasons for exclusion
Study design and study population File name of each version of the dataset and the
modifications made
Sampling strategy, number of subjects
Table of demographic and covariate information
Handling of missing data/imputation methods
for missing PK data
Handling of outliers
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provides guidelines for placement of key elements of the
results section.
Discussion section
• Audience: all readers
• Focus area: results interpretation, physiologic and
mechanistic context
A discussion of the analysis results is an integral compo-
nent of a population PK report and is intended for both
technical and non-technical readers. It should be presented
in plain language that is understandable to all stakeholders,
non-technical as well as experienced clinicians and phar-
macometricians. The discussion is not intended to simply
restate the important results, rather, its purpose is to in-
terpret the modeling results and explain their clinical
relevance in the context of prior knowledge and with an
emphasis on how the results address the project objectives.
The discussion may be challenging for report authors, since
this is the main section where the impact of the technically-
focused ‘‘Results section’’ is explained and placed in
context.
The Discussion should include comment on each of the
questions listed in ‘‘General recommendations’’ section.
Recommended elements of the discussion include:
• Summary of principal findings, e.g., impact of covari-
ates on pharmacokinetics
• Explanation of the relevance of modeling (technical)
results, for example, description of the influence of
covariates on exposure, safety and efficacy and, in turn,
on dose selection or adjustments for specific patient
subgroups
• Interpretation of the results in the context of prior
knowledge about the drug or other drugs within the
same class of compounds
• The robustness of the findings considering the assump-
tions and identified limitations of the data, model and
method with discussion of caveats
Conclusions section
• Audience: all readers
• Focus area: impact of findings
Table 6 Guidelines for placement of methods subsections
Generally included in main body of report May or may not be included
in main body of report
Usually included
in appendix
Model structure, including both a diagram and equations Construction of structural model DAP
Prior knowledge about covariate effects Identification of random effects Description of assay
methods or reference to
appropriate documentation
Software, fitting algorithm Handling of missing data during model development
Covariates to be examined Sensitivity analyses (e.g. impact of outliers)
Covariate selection methods
Model performance/validation
Simulations—methodology, inclusion of uncertainty
Statement of lower limit of assay quantitation
Table 7 Guidelines for placement of results subsections
Generally included in main body of report May or may not be included in main body
of report
Usually included in appendix
Equations describing the form of the best selected
model
Description of final analysis dataset(s) Detailed, comprehensive model
development table(s)
Final parameter estimates Reasoning for model selection—Model
development table for key models
Key model qualification plots (e.g., DV vs PRED
and IPRED, VPC)
Model qualification
Tables and/or figures illustrating simulation results
or other model applications
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The conclusion is a succinct summary of the major findings
of the analysis and their relevance, and should be written in
language that can be understood by a nontechnical audi-
ence. The conclusion may be presented as a single sum-
mative paragraph or a bullet list.
Regulatory considerations
Results from population PK analysis submitted to the
regulatory agency need to be accompanied with a struc-
tured population PK report. FDA does not have any
specific recommendations regarding the length of the in-
dividual sections of the population PK report, use of a
particular format, or inclusion of specific graphs for
population PK reporting. The intent of this section is not to
be prescriptive but to provide general expectations and
considerations regarding population PK reporting from a
regulatory perspective and also to highlight the potential
advantages that standardization may offer.
Population PK analysis and associated reports play an
important role during regulatory review. The report serves
as a primary guide for the reviewers to formulate regula-
tory decisions based on population PK modelling. The
description of the sponsor’s model and methodology help
identify parts of the analysis that need to be reproduced for
confirmation or which may need to be further developed to
ensure a complete review of the PK data. The report also
serves as a source document to providing relevant figures
(model diagnostics, forest plots relevant to the labeling
decisions etc.) and tables (description of studies, final pa-
rameter estimates etc.) that may be included in regulatory
review documents.
Therefore, it is important and usually in the sponsor’s
best interest that the above information be readily available
to reviewers in order to assist their efficient review. It must
also be recognized that review cycles are frequently short
and population PK analysis is just one of several parts of a
submission falling in the pharmacometrics reviewer’s
scope of responsibility. The sections of the proposed an-
notated label that contain information based on population
PK analysis should provide hyperlinks to the relevant
population PK report. In certain submissions, for example
those addressing pediatric indications, population PK
analysis along with exposure–response analysis might be a
central element of the review. Currently, there is substan-
tial variation in report structure, location of contents and
details within these reports. The objectives of this working
group are well-aligned with those of pharmacometric sci-
entists in regulatory agencies in facilitating the efficient
and effective review of population PK analyses.
For regulatory review, it is important that the report
synopsis is focused on the key decisions and variables of
interest. For example, if there is a dosing recommendation
for a specific population based on population PK, it is
useful to know the impact of the specific covariate on AUC
and/or Cmax (if applicable), rather than reporting only the
effects on a specific PK parameter such as CL or Vd. There
is a need and value to be gained in making these reports
accessible to an interdisciplinary audience. If the recom-
mendations outlined in this article are followed, it is hoped
that reviewers from other disciplines may be able to better
understand the rationale behind labelling recommendations
based on population PK analyses.
The review of the population PK report submitted by the
sponsor is an integral part of the pharmacometric review
process. The synopsis is one of the critical components for
FDA reviewers, providing a high level summary of the
population PK analysis and the recommendations based on
the population PK modelling. In addition, the population
PK report is usually the source of the base and final model
control streams and outputs. Therefore, it is important that
the model outputs included in the report match the model
output generated when the actual model is run by the re-
viewer using the sponsor’s model code and dataset. The
population PK report is also an important vehicle to un-
derstand the technical aspects of the population PK mod-
eling process including model development, model
evaluation, simulation etc. Moreover, key tables and fig-
ures from the sponsor’s report may be included by
regulatory reviewers when describing sponsor’s analysis in
the pharmacometric review.
Summarized below are some of the considerations for
key sections when reporting population PK results to the
regulatory agencies. Specific suggestions that may fa-
cilitate the review process include the following for each
section:
(a) Synopsis: This is the most important stand-alone
section of the population PK report summarizing
the objectives, data, methodology and recommen-
dations. The target audience of this section may be
people with minimal or no hands-on experience
with population PK analysis. It is important to
present the results in terms of effects on drug
exposure (e.g. AUC, Cmin, Cmax, Cavg) and not PK
parameters when describing the impact of covari-
ates on the pharmacokinetics. The synopsis should
also include a brief justification on why the
available data is adequate to evaluate difference
in exposures in specific populations.
(b) Data section: It is recommended that the distinction
be made between available data and final data used
for model building and evaluation. Tabulated
summaries of utilized studies should be included
summarizing number of patients, PK samples,
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demographic characteristics etc. The lower limit of
quantification should be reported. Furthermore,
justification for not including studies with readily
available and potentially informative data should
be provided. Finally, the approach used for han-
dling of outliers and missing data should be
included in this section.
(c) Methodology: This section is should be sufficiently
detailed to allow for replication of results. In
addition, key simulations used for labelling recom-
mendations resulting from the analysis should be
described in detail. Methods for incorporating vari-
ability or parameter uncertainty and deriving confi-
dence intervals, or prediction intervals should be
clearly described in the main body of the report.
(d) Results: Key results of the analysis could also be
presented utilizing format of tables or figures for
easy readability and interpretation. Apart from the
recommended elements as described in the ‘Results’
section above, the following information is also
considered helpful to pharmacometric reviewers:
(i) If the population PK model includes data
from dedicated clinical pharmacology stud-
ies (e.g. renal impairment, hepatic impair-
ment or drug interaction studies), the results
obtained from population PK should be
compared to those observed in the dedicated
studies. The consistency or inconsistency of
the results between these two approaches
(typical non-compartmental approach of
comparing PK in various groups utilized
in the dedicated clinical pharmacology
studies versus assessing the impact of a
covariate using pooled data via population
analysis)
(ii) In addition to the information on decrease
in objective function value by the inclusion
of the covariate, the information on ‘‘how
much variability is explained by inclusion
of the covariate?’’ is also useful and should
be included.
(iii) The variability in parameter estimates be-
tween subjects should be reported as %CV
while precision of the parameter estimate
should be reported as % RSE (% Relative
standard error) or 95 % CI.
(iv) Depending on the objective of the analysis,
VPC plots should be stratified by relevant
covariates to illustrate the performance of
the model in specific subgroups.
(v) A table comparing the parameter estimates
from the base and final model should be
included for easy side by side comparison.
Furthermore, in accordance to what has
been discussed above, the use of innovative
and informative visual representation of
results, that may include color, may fa-
cilitate understanding the clinical implica-
tions of the analysis is encouraged.
(e) Discussion: Apart from the recommended elements
as described in the Discussion section above, it is
also important to discuss the adequacy or inadequacy
(if it exists) of the data to support recommendations
based on the model.
(f) Appendices: At the minimum, the model code and
outputs for the base and the final model should be
included. The code and outputs of key intermediate
models may also be included as deemed necessary.
A run record detailing the steps undertaken for the
analysis should be presented. Wherever necessary,
methodology and codes for generating the key
figures other than standard diagnostic and individual
plots (e.g. figure describing simulation of an alter-
nate dosing regimen) should be provided. There is no
need to reproduce tables of individual data since this
information is already available in the analysis
dataset submitted.
(g) Electronic files: Sponsors should refer to the FDA
Pharmacometrics website [11] for general guidance
on expectations of submitting pharmacometric data
and models. It is critical that datasets and model files
submitted for the base, final and key intermediate
models are the same as those used for generating the
model outputs in the appendices of the report. It is
also important to include the unique subject identi-
fier information for each subject in the population
PK dataset that is same as used in the individual
clinical study report datasets. This information is
vital if data integration is required between the
individual level output (e.g. individual post hoc
estimates for clearance or volume of distribution)
generated from the population PK model and the
efficacy or safety datasets from the individual
clinical study reports.
Conclusions
Standardized reporting is a positive step towards the in-
dustrialization of pharmacometrics [2]. A number of pub-
lications focus either on the technical aspects [4, 7] or
reporting for a specific audience, e.g. preparation of pub-
lications involving population PK [8]. In contrast, our focus
was to provide general recommendations for reports that
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serve the dual purpose of providing a repository of tech-
nical information and a communication tool for informed
stakeholders. The intent was not to be prescriptive, but to
provide general recommendations, and thus to highlight
the potential advantages that standardization may offer
rather than to provide an exhaustive description of tech-
nical details.
Initially, a survey was implemented to elicit common
PK reporting and analysis practices among practitioners.
The survey results were used as a basis for consultation and
collaboration among practitioners from a wide experience
base, including representatives from industry, regulators
and consultants providing population PK analysis services.
Derived recommendations are general in nature and can be
utilized by different types of organizations, e.g. academic,
clinical, industry, or regulatory.
The benefits of this standardization for reviewers, in-
cluding regulators, are as follows:
(a) Clear objectives are always stated
(b) Consistency in terminology, figures and content
permits efficient review,
(c) Relevant, easy to find content increases efficiency in
interpretation,
(d) Discussion of previous findings puts the analysis
findings into a broader context.
(e) The synopsis focuses on major findings of interest
and technical detail is balanced with a decision/
recommendation focus,
(f) A well-written synopsis provides non-technical au-
dience with an understanding of the application of
population PK analysis.
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